Joseph Babigumira, MBChB, MS, PhD, has left his position as associate professor in the Department of Global Health, after nine years of service to his students, peer faculty and staff. Joseph has been an important contributor to the School of Public Health and the wider University of Washington community since he arrived in 2006 as a PhD student in the School of Pharmacy. Over the years, he has touched many of us with his thoughtfulness, sincerity, quiet activism and dry wit – we will miss him greatly.
Results to appear in Open Forum Infectious Diseases show hydroxychloroquine does not keep people from developing COVID-19.
MEDIA CONTACT: Susan Gregg, firstname.lastname@example.org, 206.390.3226
Jake Ellison, UW News
When a vaccine to fight COVID-19 has been approved by the FDA for distribution, it’s unlikely that at first there will be enough doses for everyone. Consequently, the United States will need an equitable and effective plan for who gets those first doses, how they get them and who’s next.
Just as important, that plan — like the vaccine itself — has to be trusted and accepted by the general public.
Most countries world-wide implemented localized or national school closures in response to the COVID-19 pandemic, with estimates of >65% of enrolled children globally affected by school closures.1 Since the early pandemic, schools in many settings around the world have fully or partially re-opened for in-person instruction, while in other settings schools have re-opened exclusively using online learning.
On October 1, the International Training and Education Center for Health (I-TECH) celebrated the launch of the local and independent Botswana Training and Education Center for Health (B-TECH) and Caribbean Training and Education Center for Health (C-TECH).
Video: Preserving the Scientific Integrity of Getting to COVID-19 Vaccines: From Clinical Trials to Public Allocation
More than 5,200 viewers joined us last week for the Johns Hopkins University–University of Washington symposium “Preserving the Scientific Integrity of Getting to COVID-19 Vaccines: From Clinical Trials to Public Allocation.”
To celebrate the UW School of Public Health’s 50 years of impact, the School is recognizing 50 alumni from around the world who have a demonstrated record of distinguished service and achievement across public health disciplines and settings. These 50 Changemakers of Public Health are leaders, trailblazers, educators, innovators, influencers and health equity heroes that represent just a slice of the School’s community of more than 10,000 alumni worldwide who are addressing some of the most pressing population health issues of our time.
UW Medicine, Fred Hutch scientists will jointly test whether the monoclonal drug can prevent infection among people exposed to COVID-19.
Researchers at UW Medicine and the Fred Hutchinson Cancer Research Center are jointly testing monoclonal antibodies created by Regeneron Pharmaceuticals to prevent COVID-19, and are starting to recruit patients.
How COVID-19 Affects Some People Long After They Become Infected with the Coronavirus (includes Jennifer Ross)
By Ryan Blethen Seattle Times staff reporter
Nearly eight months after the pandemic was declared, researchers are gaining a more complete understanding of how the new coronavirus affects people.
One thing they’re noticing as time goes on: some people diagnosed with COVID-19 feel sick long after contracting the virus.